{"id":41282,"date":"2026-01-02T10:56:21","date_gmt":"2026-01-02T15:56:21","guid":{"rendered":"https:\/\/www.rxbriefcase.com\/?p=41282"},"modified":"2026-01-02T10:56:21","modified_gmt":"2026-01-02T15:56:21","slug":"implementing-nk3-antagonists-in-clinical-practice","status":"publish","type":"post","link":"https:\/\/www.rxbriefcase.com\/fr\/implementing-nk3-antagonists-in-clinical-practice\/","title":{"rendered":"Implementing NK3 Antagonists in Clinical Practice"},"content":{"rendered":"<p>Neurokinin 3 (NK3) antagonists are a <strong>new class of medications<\/strong> designed to manage vasomotor symptoms (VMS), such as hot flashes and night sweats, associated with menopause. Unlike hormone therapy, NK3 antagonists work by modulating the neurokinin-3 receptors involved in the body\u2019s thermoregulation, offering an alternative for patients who cannot or prefer not to use estrogen-based treatments.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Why It Matters<\/strong><\/h3>\n\n\n\n<p>VMS affects up to <a href=\"https:\/\/journals.lww.com\/menopausejournal\/citation\/2022\/01000\/patterns_of_menstrual_cycle_length_over_the.1.aspx\">80% of women during menopause<\/a> and can significantly impact sleep, mood, and overall quality of life. While hormone therapy remains effective for many, some patients face contraindications such as a history of hormone-sensitive cancers, cardiovascular risk, or personal preference to avoid hormones. NK3 antagonists provide a non-hormonal option to address these symptoms effectively.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>How Clinicians Can Implement Them<\/strong><\/h3>\n\n\n\n<p>Practical considerations for prescribing NK3 antagonists include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dosing and titration:<\/strong> <a href=\"https:\/\/medlineplus.gov\/druginfo\/meds\/a623051.html?utm_source=chatgpt.com\">Start at the recommended dose<\/a> and adjust based on symptom control and tolerability.<br><\/li>\n\n\n\n<li><strong>Monitoring and side effects:<\/strong> <a href=\"https:\/\/www.fda.gov\/media\/181764\/download?utm_source=chatgpt.com\">Common side effects<\/a> may include headache or mild gastrointestinal symptoms. Liver function tests are recommended for some agents.<br><\/li>\n\n\n\n<li><strong>Patient counseling:<\/strong> Discuss expected symptom improvement, potential side effects, and realistic timelines to set expectations.<br><\/li>\n\n\n\n<li><strong>Clinical decision-making:<\/strong> Evaluate patient history, comorbidities, and preferences to determine if NK3 antagonists are appropriate.<\/li>\n<\/ul>\n\n\n\n<p>Integrating NK3 antagonists into practice allows clinicians to expand treatment options, address unmet patient needs, and provide personalized care for women navigating menopause.<\/p>\n\n\n\n<p>For clinicians seeking practical guidance on dosing, monitoring, and patient counseling, the <strong>30-minute accredited program \u201cImplementing NK3 Antagonists in Clinical Practice\u201d<\/strong> provides case-based insights and evidence-based strategies to confidently introduce this therapy into your practice.<\/p>\n\n\n\n<p><a href=\"https:\/\/www.mdbriefcase.com\/courses\/implementing-nk3-antagonists-in-clinical-practice\/\">Take the free course here<\/a>.\u00a0<\/p>\n\n\n\n<p><em>This program has received an unrestricted educational grant or in-kind support from Astellas Pharma Canada Inc.<\/em><\/p>","protected":false},"excerpt":{"rendered":"<p>Neurokinin 3 (NK3) antagonists are a new class of medications designed to manage vasomotor symptoms (VMS), such as hot flashes and night sweats, associated with menopause. Unlike hormone therapy, NK3 antagonists work by modulating the neurokinin-3 receptors involved in the body\u2019s thermoregulation, offering an alternative for patients who cannot or prefer not to use estrogen-based [&hellip;]<\/p>\n","protected":false},"author":5387,"featured_media":41283,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-41282","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Implementing NK3 Antagonists in Clinical Practice - RxBriefCase<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.rxbriefcase.com\/fr\/implementing-nk3-antagonists-in-clinical-practice\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Implementing NK3 Antagonists in Clinical Practice - RxBriefCase\" \/>\n<meta property=\"og:description\" content=\"Neurokinin 3 (NK3) antagonists are a new class of medications designed to manage vasomotor symptoms (VMS), such as hot flashes and night sweats, associated with menopause. Unlike hormone therapy, NK3 antagonists work by modulating the neurokinin-3 receptors involved in the body\u2019s thermoregulation, offering an alternative for patients who cannot or prefer not to use estrogen-based [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.rxbriefcase.com\/fr\/implementing-nk3-antagonists-in-clinical-practice\/\" \/>\n<meta property=\"og:site_name\" content=\"RxBriefCase\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-02T15:56:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.rxbriefcase.com\/wp-content\/uploads\/2026\/01\/shutterstock_2529290037-1024x683.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"683\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Katie Dangerfield\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Katie Dangerfield\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.rxbriefcase.com\/implementing-nk3-antagonists-in-clinical-practice\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.rxbriefcase.com\/implementing-nk3-antagonists-in-clinical-practice\/\"},\"author\":{\"name\":\"Katie Dangerfield\",\"@id\":\"https:\/\/www.rxbriefcase.com\/#\/schema\/person\/d424f568bd24ff51b89542a2c3055f49\"},\"headline\":\"Implementing NK3 Antagonists in Clinical Practice\",\"datePublished\":\"2026-01-02T15:56:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.rxbriefcase.com\/implementing-nk3-antagonists-in-clinical-practice\/\"},\"wordCount\":280,\"publisher\":{\"@id\":\"https:\/\/www.rxbriefcase.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.rxbriefcase.com\/implementing-nk3-antagonists-in-clinical-practice\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.rxbriefcase.com\/wp-content\/uploads\/2026\/01\/shutterstock_2529290037.jpg\",\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"fr-CA\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.rxbriefcase.com\/implementing-nk3-antagonists-in-clinical-practice\/\",\"url\":\"https:\/\/www.rxbriefcase.com\/implementing-nk3-antagonists-in-clinical-practice\/\",\"name\":\"Implementing NK3 Antagonists in Clinical Practice - RxBriefCase\",\"isPartOf\":{\"@id\":\"https:\/\/www.rxbriefcase.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.rxbriefcase.com\/implementing-nk3-antagonists-in-clinical-practice\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.rxbriefcase.com\/implementing-nk3-antagonists-in-clinical-practice\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.rxbriefcase.com\/wp-content\/uploads\/2026\/01\/shutterstock_2529290037.jpg\",\"datePublished\":\"2026-01-02T15:56:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.rxbriefcase.com\/implementing-nk3-antagonists-in-clinical-practice\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.rxbriefcase.com\/implementing-nk3-antagonists-in-clinical-practice\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/www.rxbriefcase.com\/implementing-nk3-antagonists-in-clinical-practice\/#primaryimage\",\"url\":\"https:\/\/www.rxbriefcase.com\/wp-content\/uploads\/2026\/01\/shutterstock_2529290037.jpg\",\"contentUrl\":\"https:\/\/www.rxbriefcase.com\/wp-content\/uploads\/2026\/01\/shutterstock_2529290037.jpg\",\"width\":8192,\"height\":5464},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.rxbriefcase.com\/implementing-nk3-antagonists-in-clinical-practice\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.rxbriefcase.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Implementing NK3 Antagonists in Clinical Practice\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.rxbriefcase.com\/#website\",\"url\":\"https:\/\/www.rxbriefcase.com\/\",\"name\":\"RxBriefCase\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.rxbriefcase.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.rxbriefcase.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.rxbriefcase.com\/#organization\",\"name\":\"RxBriefCase\",\"url\":\"https:\/\/www.rxbriefcase.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/www.rxbriefcase.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.rxbriefcase.com\/wp-content\/uploads\/2024\/07\/logo.webp\",\"contentUrl\":\"https:\/\/www.rxbriefcase.com\/wp-content\/uploads\/2024\/07\/logo.webp\",\"width\":190,\"height\":36,\"caption\":\"RxBriefCase\"},\"image\":{\"@id\":\"https:\/\/www.rxbriefcase.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.rxbriefcase.com\/#\/schema\/person\/d424f568bd24ff51b89542a2c3055f49\",\"name\":\"Katie Dangerfield\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/1dd44d993db807e9567f49674bdf45f95be0412e401a723dc67b4a07037743b0?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1dd44d993db807e9567f49674bdf45f95be0412e401a723dc67b4a07037743b0?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1dd44d993db807e9567f49674bdf45f95be0412e401a723dc67b4a07037743b0?s=96&d=mm&r=g\",\"caption\":\"Katie Dangerfield\"},\"url\":\"https:\/\/www.rxbriefcase.com\/fr\/author\/katie-dangerfieldthinkresearch-com\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Implementing NK3 Antagonists in Clinical Practice - RxBriefCase","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.rxbriefcase.com\/fr\/implementing-nk3-antagonists-in-clinical-practice\/","og_locale":"fr_CA","og_type":"article","og_title":"Implementing NK3 Antagonists in Clinical Practice - RxBriefCase","og_description":"Neurokinin 3 (NK3) antagonists are a new class of medications designed to manage vasomotor symptoms (VMS), such as hot flashes and night sweats, associated with menopause. Unlike hormone therapy, NK3 antagonists work by modulating the neurokinin-3 receptors involved in the body\u2019s thermoregulation, offering an alternative for patients who cannot or prefer not to use estrogen-based [&hellip;]","og_url":"https:\/\/www.rxbriefcase.com\/fr\/implementing-nk3-antagonists-in-clinical-practice\/","og_site_name":"RxBriefCase","article_published_time":"2026-01-02T15:56:21+00:00","og_image":[{"width":1024,"height":683,"url":"https:\/\/www.rxbriefcase.com\/wp-content\/uploads\/2026\/01\/shutterstock_2529290037-1024x683.jpg","type":"image\/jpeg"}],"author":"Katie Dangerfield","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Katie Dangerfield","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.rxbriefcase.com\/implementing-nk3-antagonists-in-clinical-practice\/#article","isPartOf":{"@id":"https:\/\/www.rxbriefcase.com\/implementing-nk3-antagonists-in-clinical-practice\/"},"author":{"name":"Katie Dangerfield","@id":"https:\/\/www.rxbriefcase.com\/#\/schema\/person\/d424f568bd24ff51b89542a2c3055f49"},"headline":"Implementing NK3 Antagonists in Clinical Practice","datePublished":"2026-01-02T15:56:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.rxbriefcase.com\/implementing-nk3-antagonists-in-clinical-practice\/"},"wordCount":280,"publisher":{"@id":"https:\/\/www.rxbriefcase.com\/#organization"},"image":{"@id":"https:\/\/www.rxbriefcase.com\/implementing-nk3-antagonists-in-clinical-practice\/#primaryimage"},"thumbnailUrl":"https:\/\/www.rxbriefcase.com\/wp-content\/uploads\/2026\/01\/shutterstock_2529290037.jpg","articleSection":["Uncategorized"],"inLanguage":"fr-CA"},{"@type":"WebPage","@id":"https:\/\/www.rxbriefcase.com\/implementing-nk3-antagonists-in-clinical-practice\/","url":"https:\/\/www.rxbriefcase.com\/implementing-nk3-antagonists-in-clinical-practice\/","name":"Implementing NK3 Antagonists in Clinical Practice - RxBriefCase","isPartOf":{"@id":"https:\/\/www.rxbriefcase.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.rxbriefcase.com\/implementing-nk3-antagonists-in-clinical-practice\/#primaryimage"},"image":{"@id":"https:\/\/www.rxbriefcase.com\/implementing-nk3-antagonists-in-clinical-practice\/#primaryimage"},"thumbnailUrl":"https:\/\/www.rxbriefcase.com\/wp-content\/uploads\/2026\/01\/shutterstock_2529290037.jpg","datePublished":"2026-01-02T15:56:21+00:00","breadcrumb":{"@id":"https:\/\/www.rxbriefcase.com\/implementing-nk3-antagonists-in-clinical-practice\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.rxbriefcase.com\/implementing-nk3-antagonists-in-clinical-practice\/"]}]},{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.rxbriefcase.com\/implementing-nk3-antagonists-in-clinical-practice\/#primaryimage","url":"https:\/\/www.rxbriefcase.com\/wp-content\/uploads\/2026\/01\/shutterstock_2529290037.jpg","contentUrl":"https:\/\/www.rxbriefcase.com\/wp-content\/uploads\/2026\/01\/shutterstock_2529290037.jpg","width":8192,"height":5464},{"@type":"BreadcrumbList","@id":"https:\/\/www.rxbriefcase.com\/implementing-nk3-antagonists-in-clinical-practice\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.rxbriefcase.com\/"},{"@type":"ListItem","position":2,"name":"Implementing NK3 Antagonists in Clinical Practice"}]},{"@type":"WebSite","@id":"https:\/\/www.rxbriefcase.com\/#website","url":"https:\/\/www.rxbriefcase.com\/","name":"Mallette Rx","description":"","publisher":{"@id":"https:\/\/www.rxbriefcase.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.rxbriefcase.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.rxbriefcase.com\/#organization","name":"Mallette Rx","url":"https:\/\/www.rxbriefcase.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.rxbriefcase.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.rxbriefcase.com\/wp-content\/uploads\/2024\/07\/logo.webp","contentUrl":"https:\/\/www.rxbriefcase.com\/wp-content\/uploads\/2024\/07\/logo.webp","width":190,"height":36,"caption":"RxBriefCase"},"image":{"@id":"https:\/\/www.rxbriefcase.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.rxbriefcase.com\/#\/schema\/person\/d424f568bd24ff51b89542a2c3055f49","name":"Katie Dangerfield","image":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/secure.gravatar.com\/avatar\/1dd44d993db807e9567f49674bdf45f95be0412e401a723dc67b4a07037743b0?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/1dd44d993db807e9567f49674bdf45f95be0412e401a723dc67b4a07037743b0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1dd44d993db807e9567f49674bdf45f95be0412e401a723dc67b4a07037743b0?s=96&d=mm&r=g","caption":"Katie Dangerfield"},"url":"https:\/\/www.rxbriefcase.com\/fr\/author\/katie-dangerfieldthinkresearch-com\/"}]}},"_links":{"self":[{"href":"https:\/\/www.rxbriefcase.com\/fr\/wp-json\/wp\/v2\/posts\/41282","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rxbriefcase.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.rxbriefcase.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.rxbriefcase.com\/fr\/wp-json\/wp\/v2\/users\/5387"}],"replies":[{"embeddable":true,"href":"https:\/\/www.rxbriefcase.com\/fr\/wp-json\/wp\/v2\/comments?post=41282"}],"version-history":[{"count":0,"href":"https:\/\/www.rxbriefcase.com\/fr\/wp-json\/wp\/v2\/posts\/41282\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.rxbriefcase.com\/fr\/wp-json\/wp\/v2\/media\/41283"}],"wp:attachment":[{"href":"https:\/\/www.rxbriefcase.com\/fr\/wp-json\/wp\/v2\/media?parent=41282"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.rxbriefcase.com\/fr\/wp-json\/wp\/v2\/categories?post=41282"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.rxbriefcase.com\/fr\/wp-json\/wp\/v2\/tags?post=41282"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}